8-K: Creative Medical Tech Acquires BioDefense Stake

Creative Medical Technology Holdings, Inc. has acquired a controlling 80% stake in BioDefense, Inc. through a stock purchase agreement.

Summary

• Creative Medical Technology Holdings, Inc. (the Company) entered into a Stock Purchase Agreement with Creative Acquisition Corp. (CAC) on September 24, 2026.
• The Company purchased 4,000,000 shares of BioDefense, Inc. common stock from CAC.
• The purchase price consisted of $200,000 in cash and 1,000,000 shares of the Company's common stock.
• Following the transaction, the Company now owns 16,000,000 shares, representing 80% of BioDefense, Inc.'s outstanding common stock.
• CAC retains 4,000,000 shares, or 20% of BioDefense, Inc.'s outstanding common stock.
• Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc., is also the CEO of CAC and indirectly owns all of its shares.
• The shares of the Company's common stock issued to CAC were part of a private placement under Section 4(a)(2) of the Securities Act of 1933.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily due to the strategic acquisition of a controlling stake in BioDefense, Inc., though the transaction involves related parties and unregistered securities.

Positives

• Acquisition of a controlling 80% stake in BioDefense, Inc., potentially enhancing the Company's strategic position and market reach.
• The transaction diversifies the Company's holdings and could lead to synergistic opportunities.

Negatives

• The transaction involves related parties, as the CEO of Creative Medical Technology Holdings, Inc. is also the CEO of Creative Acquisition Corp.
• The shares of Creative Medical Technology Holdings, Inc. issued as part of the purchase price were issued in a private placement and are subject to restrictions on resale.
• The purchase price includes a significant cash component ($200,000) which impacts liquidity.

Risks

• The shares of Creative Medical Technology Holdings, Inc. issued to CAC are unregistered and subject to holding periods and potential resale restrictions under Rule 144.
• Potential conflicts of interest due to the related party nature of the transaction.
• The value and future performance of BioDefense, Inc. are subject to market and operational risks.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the future outlook of BioDefense, Inc. or the combined entities. The focus is on the completion of the acquisition.

Management Comments

• Timothy Warbington, President and Chief Executive Officer of the Company, is also the Chairman and Chief Executive Officer of CAC.
• Donald Dickerson, Chief Financial Officer of the Company, signed the Stock Purchase Agreement on behalf of the Purchaser.

Industry Context

StockSavvy.ai notes that strategic acquisitions, even those involving private placements and related parties, are common in the biotechnology and medical technology sectors as companies seek to consolidate market share, acquire new technologies, or expand their product pipelines. The acquisition of a controlling stake in BioDefense, Inc. by Creative Medical Technology Holdings, Inc. aligns with this trend.

Related Party Transactions

• Creative Medical Technology Holdings, Inc. purchased shares of BioDefense, Inc. from Creative Acquisition Corp. (CAC).
• Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc., is also the CEO of CAC and indirectly owns all of its shares, indicating a related party transaction.

Stakeholder Impact

• Shareholders of Creative Medical Technology Holdings, Inc.: Potential dilution from the issuance of 1,000,000 shares of common stock. The strategic benefit of acquiring BioDefense, Inc. may offset dilution concerns.
• Shareholders of BioDefense, Inc.: The 20% minority shareholders (CAC) will now be subject to the control of Creative Medical Technology Holdings, Inc.
• Creditors: No immediate impact is indicated, but future financial performance of the combined entity will be relevant.

Next Steps

• Integration of BioDefense, Inc. operations and strategy with Creative Medical Technology Holdings, Inc.
• Management of the 1,000,000 shares of Creative Medical Technology Holdings, Inc. common stock issued to CAC, considering their unregistered status and resale restrictions.

Key Dates

Recommendation

The acquisition of a controlling stake in BioDefense, Inc. is a significant strategic move. However, the transaction involves related parties and unregistered securities, introducing complexities and potential risks. The cash outlay also impacts liquidity. Without further financial details on BioDefense, Inc. or a clearer integration plan, a 'hold' recommendation is prudent, allowing for further observation of the strategic benefits and potential challenges.

Keywords

BioDefense, Inc., Stock Purchase Agreement, Acquisition, Controlling Stake, Private Placement, Related Party Transaction, Unregistered Securities